Page 4 - Pediatric Study Plan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 18-May-2021 EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous 18.05.2021 / 07:00 Geneva, Switzerland, May 18, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)(" Relief"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today provided an update on the development of ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be both taste-masked and immediate release, in the lead indication, urea cyc...

Relief"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today provided an update on the development of ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be both taste-masked and immediate release, in the lead indication, urea cycle disorders (UCDs). UCDs are a group of rare genetic metabolic disorders which can lead to an excess accumulation of ammonia in the bloodstream, causing different symptoms such as somnolence, coma, and, in the worst case, may lead to mu...